Yarrow Bioscience (YARW)
Develops a TSHR-blocking antibody for Graves’ disease and thyroid eye disease.
Something off on this page? Send us feedback.
Develops YB-101, a subcutaneous antibody intended to block TSHR in Graves’ disease and thyroid eye disease. The company has no product revenue and concentrates its operating work, licensed ex-China rights, and future economics on that single clinical program.
Develops YB-101, a subcutaneously administered antibody designed to block the thyroid-stimulating-hormone receptor in Graves’ disease and thyroid eye disease. The program aims to address thyroidal and extra-thyroidal manifestations through one molecule. Its own study is enrolling in the United States and Australia, while GenSci runs related studies in China.
Operates with a single licensed development asset rather than a commercial product business. Yarrow holds rights outside China, where it directs development and would commercialize an approved therapy; GenSci retains Chinese rights and provides data central to the thyroid eye disease strategy. Execution depends on clinical results, FDA and other approvals, GenSci’s license and partner work, external research and manufacturing providers, and additional funding.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $22.9M · Total debt $0 · Total assets $23.6M · Shareholders' equity $22.1M
- Revenue
- $97.0K
- Operating income
- −$3.1M
- Net income
- −$3.0M
To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 24, 2026 | Jul 22 | $0.008 |
2.67M company shares as of Sep 3, 2026 · holders as of their latest filing
Two share counts disagree (2.67M in the company's Sep 3, 2026 report, 17.2K elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
ADAR1 Capital Management, LLCStrategic | —8.80% of class, as filed | — | 13Gfiled Aug 14, 2026 ↗ |
AI Biotechnology LLCStrategic | —6.02% of class, as filed | — | 13Dfiled Jul 29, 2026 ↗ |
JANUS HENDERSON GROUP Ltd.Strategic | —9.99% of class, as filed | — | 13Gfiled Aug 7, 2026 ↗ |
Logos Global Management LPInstitution | —9.90% of class, as filed | — | 13Gfiled Aug 4, 2026 ↗ |
Orbimed Advisors LLCInstitution | —9.97% of class, as filed | — | 13Dfiled Aug 5, 2026 ↗ |
| See all 8 → | |||
13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
Nothing filed in the last 12 months.
- Amgen
Established TED franchise plus subcutaneous delivery expansion.
- Viridian Therapeutics
Approved TED therapy plus late-stage and same-target follow-ons.
- Biohaven
Pivotal Graves' therapy that clears disease-driving TSHR antibodies.
- Roivant Sciences
Registrational FcRn blocker for Graves' disease.
- argenx (ADR)
Registrational FcRn program in Graves' disease.
- Novartis (ADR)
Phase 2 anti-IL-6 program in thyroid eye disease.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Yarrow Bioscience | $29.83 | −3.71% | $515.5K | — | — | 1.1 | +40.6% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Viridian Therapeutics | $22.51 | −1.18% | $2.58B | — | — | 36.3 | +278.7% |
| Biohaven | $15.69 | −0.13% | $2.36B | — | — | — | — |
| Roivant Sciences | $34.21 | −0.90% | $24.69B | — | — | 3,278.3 | −33.6% |
| argenx (ADR) | $1,055.50 | +2.62% | $65.63B | 38.5 | — | 12.5 | — |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Median | 27.5 | 18.1 | 12.5 | +5.3% |